Alemtuzumab in Treating Patients With Waldenstrom's Macroglobulinemia

NCT00081068 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Conditions

Lymphoma

Interventions

BIOLOGICAL: alemtuzumab

Sponsor

Jonsson Comprehensive Cancer Center

Collaborators

[object Object]